Table 2.
Prevalence of the variables present in the CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2 scores and average scores
| Systemic arterial hypertension (%) | 80 |
| Systolic blood pressure > 160 mmHg (%) | 10 |
| Diabetes Mellitus (%) | 30 |
| Congestive heart failure and ejection fraction < 40% (%) | 30 |
| Cardiovascular disease (%) | 23.3 |
| Stroke or transient ischemic accident (%) | 16.7 |
| Liver disease* (%) | 0 |
| Kidney disease † (%) | 6.7 |
| Pulmonary disease (%) | 16.7 |
| Labile or difficult-to-control INR ‡ (%) | 23.3 |
| History of or predisposition to major bleeding (%) | 16.7 |
| Use of antiplatelet or anti-inflammatory agents (%) | 26.7 |
| Use of medications that interact with coumarins (%) | 43.3 |
| Abusive use of alcohol (%) | 3.3 |
| Smoking (%) | 10 |
| CHA2DS2-VASc ≥ 2 § (%) | 86.6 |
| CHA2DS2-VASc per score (%) | |
| 0 | 3.3 |
| 1 | 10 |
| 2 | 23.4 |
| 3 | 23.4 |
| 4 | 20 |
| 5 | 13.3 |
| 7 | 3.3 |
| 8 | 3.3 |
| Mean CHA2DS2-VASc | 3 ± 1.8 |
| Mean HAS-BLED | 2 ± 1.2 |
| SAMe-TT2R2 ≥ 2 // (%) | 76.6 |
*
Chronic liver disease (e.g.: cirrhosis), or biochemical evidence of significant liver dysfunction (bilirubin > 2 - 3 times the upper level, transaminase or alkaline phosphatase > 3 times the upper level);
†
Chronic hemodialysis, kidney transplant, serum creatinine > 2.2 mg/dl;
‡
in the target range < 60% of times;
§
A score ≥ 2 indicates the necessity of anticoagulation;// A score ≥ indicates patients who require additional interventions to achieve an acceptable anticoagulation control with coumarins.